Vontobel Holding Ltd. Makes New $2.89 Million Investment in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Vontobel Holding Ltd. acquired a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the fourth quarter, Holdings Channel.com reports. The firm acquired 142,510 shares of the company’s stock, valued at approximately $2,887,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in FDMT. Swiss National Bank increased its holdings in 4D Molecular Therapeutics by 6.9% in the first quarter. Swiss National Bank now owns 57,000 shares of the company’s stock worth $862,000 after purchasing an additional 3,700 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of 4D Molecular Therapeutics by 29.7% during the 1st quarter. JPMorgan Chase & Co. now owns 367,545 shares of the company’s stock worth $5,557,000 after buying an additional 84,158 shares during the period. Bank of New York Mellon Corp increased its stake in shares of 4D Molecular Therapeutics by 1.1% in the 1st quarter. Bank of New York Mellon Corp now owns 101,322 shares of the company’s stock valued at $1,532,000 after acquiring an additional 1,136 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of 4D Molecular Therapeutics by 55.4% during the 1st quarter. MetLife Investment Management LLC now owns 17,379 shares of the company’s stock valued at $263,000 after acquiring an additional 6,197 shares during the period. Finally, Rhumbline Advisers boosted its stake in 4D Molecular Therapeutics by 14.3% during the first quarter. Rhumbline Advisers now owns 35,097 shares of the company’s stock worth $531,000 after acquiring an additional 4,382 shares in the last quarter. 99.27% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 1st. Barclays began coverage on 4D Molecular Therapeutics in a research note on Monday. They issued an “overweight” rating for the company. Royal Bank of Canada upped their price target on 4D Molecular Therapeutics from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday. BMO Capital Markets reduced their price objective on 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, April 1st. Finally, The Goldman Sachs Group restated a “buy” rating and set a $81.00 price objective on shares of 4D Molecular Therapeutics in a report on Wednesday, February 7th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of “Buy” and an average target price of $44.22.

Insider Activity at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 6,244 shares of 4D Molecular Therapeutics stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $27.50, for a total transaction of $171,710.00. Following the transaction, the insider now directly owns 1,737 shares of the company’s stock, valued at approximately $47,767.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other 4D Molecular Therapeutics news, insider Robert Young Kim sold 24,552 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $30.05, for a total value of $737,787.60. Following the completion of the sale, the insider now owns 1,043 shares in the company, valued at approximately $31,342.15. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Scott Bizily sold 6,244 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $27.50, for a total transaction of $171,710.00. Following the transaction, the insider now directly owns 1,737 shares in the company, valued at approximately $47,767.50. The disclosure for this sale can be found here. In the last three months, insiders sold 149,638 shares of company stock valued at $4,179,299. 10.70% of the stock is owned by insiders.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ FDMT opened at $24.78 on Friday. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -9.32 and a beta of 2.87. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $9.44 and a fifty-two week high of $36.25. The firm’s 50-day simple moving average is $28.97 and its 200 day simple moving average is $20.13.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.09). The company had revenue of ($0.02) million during the quarter, compared to analysts’ expectations of $4.67 million. 4D Molecular Therapeutics had a negative return on equity of 34.14% and a negative net margin of 436.30%. On average, sell-side analysts predict that 4D Molecular Therapeutics, Inc. will post -3.03 EPS for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.